Cat. No.: HY-100543

Zenidolol

(Synonyms: ICI-118551)

47 Cited Publications

Customer Review

Based on 47 publication(s) in Google Scholar

Zenidolol (ICI-118551) is a selective β2-adrenergic receptor antagonist with K_i values of Zenidolol for β2, β1 and β3 adrenergic receptors of 0.7, 49.5 and 611 nM, respectively. Zenidolol exerts antitumor effects via inducing apoptosis, inhibiting tumor sphere formation, and downregulating the HIF pathway by blocking β2-AR on tumor cells. Zenidolol exhibits a unique pulmonary vessel-specific vasodilatory effect in mouse models. Zenidolol can be used as an intraocular pressure-lowering agent in ophthalmic disease research.

For research use only. We do not sell to patients.

Purity: 99.60%
CAS No.: 72795-26-7
Formula: C₁₇H₂₇NO₂
Molecular Weight:277.40

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Zenidolol Chemical Structure

CAS No.: 72795-26-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (47)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All Adrenergic Receptor Isoforms :

All Caspase Isoforms :

All Bcl-2 Family Isoforms :

All HIF/HIF Prolyl-Hydroxylase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
Sf9	IC₅₀	0.003 μM Compound: (rac)-5, ICI-118551	Displacement of [3H]CGP1217 from human recombinant adrenergic beta2 receptor transfected in insect Sf9 cells by scintillation counting Displacement of [3H]CGP1217 from human recombinant adrenergic beta2 receptor transfected in insect Sf9 cells by scintillation counting	[PMID: 19245211]

In Vitro

Zenidolol (0-200 μM; 48 h) reduces the cell viability of primary cultured hemangioblastomas derived from VHL in a dose-dependent manner, and exhibits higher specificity for HB cells compared with HUVECs^[1].
Zenidolol (100 μM; 7 days) inhibits glomeruloid body formation in primary cultures of hemangioblastomas derived from VHL tumors^[1].
Zenidolol (100 μM; 6 h) inhibits endothelial cell migration and angiogenesis in human umbilical vein endothelial cells (HUVECs)^[1].
Zenidolol (100 μM; 48 h) attenuates hypoxia-induced nuclear translocation of HIF-1α in human umbilical vein endothelial cells (HUVECs) and primary cultures of VHL-derived hemangioblastomas^[1].
Zenidolol (100 μM; 72 h) induces apoptosis in primary cultures of VHL-derived hemangioblastomas by increasing caspase 3/7/9 activity and upregulating the pro-apoptotic gene BAX^[1].
Zenidolol (100 μM; 48-72 h) inhibits the expression of AQP-1, a HIF target gene, in primary cultures of hemangioblastoma derived from VHL^[1].
Zenidolol (10 μM) induces nitric oxide production in bovine pulmonary artery endothelial cells and promotes phosphorylation of the Ser1177 site of endothelial nitric oxide synthase^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

von Hippel-Lindau (VHL) disease-derived hemangioblastoma (HB) primary cultures, human umbilical vein endothelial cells (HUVECs)
Concentration:

0, 25, 50, 100 and 200 μM
Incubation Time:

48 h
Result:

Decreased the viability of HB primary culture cells in a dose-dependent manner, with viability dropping to 40-45% at 100 μM compared to untreated cells. Maintained HUVEC viability at 80% at 100 μM compared to untreated cells.

Cell Migration Assay^[1]

Cell Line:

human umbilical vein endothelial cells (HUVECs)
Concentration:

100 μM
Incubation Time:

6 h
Result:

Delayed wound closure in HUVECs, significantly impairing endothelial cell migration compared to untreated controls.

Immunofluorescence^[1]

Cell Line:

hypoxia-induced human umbilical vein endothelial cells (HUVECs), von Hippel-Lindau (VHL) disease-derived hemangioblastoma (HB) primary cultures
Concentration:

100 μM
Incubation Time:

48 h
Result:

Shifted HIF-1α localization from predominantly nuclear to a mix of cytoplasmic and nuclear in DFO-treated HUVECs compared to controls.
Reduced nuclear HIF-1α localization in HB cells compared to untreated controls, where HIF-1α was mainly nuclear.

Apoptosis Analysis^[1]

Cell Line:

von Hippel-Lindau (VHL) disease-derived hemangioblastoma (HB) primary cultures
Concentration:

100 μM
Incubation Time:

72 h
Result:

Induced a 1.7-fold increase in caspase 3/7 activity in HB cells compared to untreated controls. Significantly upregulated mRNA expression of BAX (1.3-2 fold) and Caspase 9 (1.3-2 fold) compared to untreated controls.

Real Time qPCR^[1]

Cell Line:

von Hippel-Lindau (VHL) disease-derived hemangioblastoma (HB) primary cultures (HB19, HB23, HB28)
Concentration:

100 μM
Incubation Time:

48 and 72 h
Result:

Significantly decreased mRNA expression of AQP-1 (a HIF-1α target gene) in multiple HB primary cultures compared to untreated controls.

Western Blot Analysis^[4]

Cell Line:

bovine pulmonary arterial endothelial cells (bPAECs)
Concentration:

10 μM
Incubation Time:

2, 5, 10 minutes
Result:

Induced time-dependent phosphorylation of eNOS at Ser1177, with normalized p-eNOS/β-actin values increasing over the 10-minute incubation period.

In Vivo

Zenidolol (5-500 μg/kg; i.v.; cumulative administration) is a potent β2-selective adrenergic receptor antagonist. In anesthetized Beagle dogs, its affinity for vascular β2-receptors is at least 250-fold higher than that for cardiac β1-receptors^[2].
Zenidolol (50-1000 μg/kg; i.v.; cumulative administration) at doses that block vascular β2-adrenoceptors does not affect the cardiac responses to sympathetic nerve stimulation in anesthetized Beagle dogs, whereas the high dose (1 mg/kg) inhibits SNS-induced heart rate elevation^[2].
Zenidolol (0.25-2.0%, 30 μg/kg; topical ocular administration, subcutaneous administration; single dose) is a potent ocular hypotensive agent with extremely low cardiac side effects, and it weakly blocks cardiac β-adrenergic receptor-mediated responses^[3].
Zenidolol (0.2 mg/kg; intravenous injection via jugular vein; single administration) significantly reduces pulmonary arterial systolic pressure in mice, but has no effect on systemic arterial systolic pressure^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Beagle dogs (either sex, weight 10-15 kg, anaesthetised with pentobarbitone sodium)^[2]
Dosage:

5, 10, 20, 40, 100, 200, 500 μg/kg
Administration:

i.v.; cumulative; each dose given 10 minutes before isoproterenol dose-response curve construction
Result:

Caused a dose-dependent parallel shift to the right of the isoproterenol vasodilator curve; did not significantly alter isoproterenol chronotropic response curves even at the highest dose of 500 μg/kg (0.5 mg/kg); showed an effective dissociation constant (Kᵦ') of 2.1 μg/kg at vascular β₂-receptors; exhibited at least a 250-fold greater affinity for vascular β₂-receptors than cardiac β₁-receptors.

Animal Model:

Beagle dogs (either sex, weight 10-18 kg, anaesthetised with pentobarbitone sodium)^[2]
Dosage:

50, 200, 1000 μg/kg (1 mg/kg)
Administration:

i.v.; cumulative
Result:

Caused a 10-30-fold shift to the right of the isoproterenol vasodilator dose-response curve at 50, 200 μg/kg without significantly reducing heart rate increases due to sympathetic nerve stimulation (SNS); induced significant antagonism of the SNS chronotropic response at the highest dose of 1000 μg/kg (1 mg/kg).

Animal Model:

Beagle dogs (either sex, weight 10-17 kg, anaesthetised with pentobarbitone sodium)^[2]
Dosage:

10, 20, 40, 100, 200, 1000 μg/kg
Administration:

i.v.; cumulative
Result:

Produced no significant changes in resting heart rate, LV dP/dtₘₐₓ, diastolic blood pressure, or AVCT over the dose range 10-1000 μg/kg; caused a trend toward reduced aortic flow, likely due to prolonged anaesthesia rather than the reagent itself.

Animal Model:

New Zealand white (male, 2-4 kg)^[3]
Dosage:

0.25%, 0.5%, 1.0%, 2.0% (topical ocular IOP studies); 30 μg/kg (subcutaneous IOP studies); 1% (topical ocular cardiac response study)
Administration:

topical ocular, 50 μl or two 25 μl doses 5 min apart; s.c., single dose
Result:

Caused a dose-dependent IOP decrease (maximal 4.2 mmHg at 1% at 1 hour post-administration; significant decreases at 0.25%, 0.5%, 1.0%, 2.0%).
Showed a greater and more prolonged IOP decrease in time-course studies, with maximal effect at 1-3 hours and persistence beyond 4 hours.
Induced a rapid IOP decrease (maximal at 1 hour, returning to normal by 6 hours) after subcutaneous 30 μg/kg administration.
Exhibited an IC₅₀ of 176 μg/kg for blocking isoprenaline-induced cardio-acceleration when given systemically. Produced no effect on cardiac response to isoprenaline when given topically.

Animal Model:

KO mice (C57/Bl6)^[4]
Dosage:

0.2 mg/kg
Administration:

Intravenous injection via jugular vein; single administration
Result:

Significantly reduced pulmonary artery systolic pressure (by approximately 25%), but has no effect on systemic artery systolic pressure.

Chemical Information

CAS No. 72795-26-7
Appearance Solid
Molecular Weight 277.40
Formula C₁₇H₂₇NO₂
Color White to off-white
SMILES

C[C@@H](NC(C)C)[C@@H](O)COC1=CC=C(C)C2=C1CCC2
Synonyms

ICI-118551
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (47)

All Cell Proliferation/Viability AssayIFWBCell Imaging/Staining

Sort by:

Journal Impact Factor

Cancer Cell

Macrophage-mediated brain-bone marrow crosstalk promotes chronic stress-induced glioma growth. [Abstract]

2026 Jun 18:S1535-6108(26)00263-1. PMID: 42314665
Immunity

Hyperactivation of sympathetic nerves fuels basophil infiltration in atopic dermatitis. [Abstract]

2026 Mar 10;59(3):598-617.e11. PMID: 41722568
Cancer Discov

Neuro-mesenchymal interaction mediated by a β2 adrenergic-nerve growth factor feedforward loop promotes colorectal cancer progression. [Abstract]

2025 Jan 13;15(1):202-226. PMID: 39137067
Cancer Res

Netrin-1 Promotes Pancreatic Tumorigenesis and Innervation through NEO1. [Abstract]

2025 Dec 31. PMID: 41474982
Nat Commun

A brain-to-liver signal mediates the inhibition of liver regeneration under chronic stress in mice. [Abstract]

2024 Nov 28;15(1):10361. PMID: 39609433
Nat Commun

Reduced hepatic bradykinin degradation accounts for cold-induced BAT thermogenesis and WAT browning in male mice. [Abstract]

2023 May 2;14(1):2523. PMID: 37130842
Nat Commun

Fat mass and obesity-associated protein regulates RNA methylation associated with depression-like behavior in mice. [Abstract]

2021 Nov 26;12(1):6937. PMID: 34836959
Nat Commun

DeSiphering receptor core-induced and ligand-dependent conformational changes in arrestin via genetic encoded trimethylsilyl 1H-NMR probe. [Abstract]

2020 Sep 25;11(1):4857. PMID: 32978402
J Exp Clin Cancer Res

Mammalian Eps15 homology domain 1 potentiates angiogenesis of non-small cell lung cancer by regulating β2AR signaling. [Abstract]

2019 Apr 25;38(1):174. PMID: 31023336
Adv Sci (Weinh)

Norepinephrine Induces Sertoli Cell Ferroptosis via Receptors Desensitization Causing Stress-Related Male Reproductive Dysfunction. [Abstract]

2025 Oct 6:e04817. PMID: 41051274

Zenidolol purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Oct 6:e04817. [Abstract]

Zenidolol (ICI118551; ICI) (1 µM; 24-72 H) reversed the NE‐induced reduction in Sertoli cell viability.

Zenidolol purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Oct 6:e04817. [Abstract]

Zenidolol (ICI118551; ICI) (1 µM) reversed NE-induced ACSL4 increase and GPX4 decrease in Sertoli cells.

Zenidolol purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Oct 6:e04817. [Abstract]

Zenidolol (ICI118551; ICI) (1 µM) reversed NE-induced alterations in the expression of SLC7A11, GPX4, and ACSL4 in TM4 cells.

Zenidolol purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Oct 6:e04817. [Abstract]

Zenidolol (ICI118551; ICI) (1 µM) alleviated the NE-induced increase in death of TM4 cells.

Zenidolol purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Oct 6:e04817. [Abstract]

Zenidolol (ICI118551; ICI) (1 µM) normalized tight junction markers ZO-1 and Claudin-11 protein levels in TM4 cells suppressed by NE.
Adv Sci (Weinh)

Sleep Deprivation Triggers the Excessive Activation of Ovarian Primordial Follicles via β2 Adrenergic Receptor Signaling. [Abstract]

2024 Nov;11(41):e2402393. PMID: 39229959
Sci Adv

Sympathetic nerve aggravates autoimmune skin disease via NE-adrenergic receptor axis: Neuroimmune cross-talk insights from vitiligo. [Abstract]

2026 Mar 6;12(10):eaea7017. PMID: 41779853
Sci Adv

Beta2 adrenergic receptor-mediated abnormal myelopoiesis drives neuroinflammation in aged patients with traumatic brain injury. [Abstract]

2024 Jul 19;10(29):eadp5239. PMID: 39028822
Int J Biol Sci

Chronic stress promotes colorectal cancer progression by enhancing glycolysis through β2-AR/CREB1 signal pathway. [Abstract]

2023 Apr 2;19(7):2006-2019. PMID: 37151872

Zenidolol purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2023 Apr 2;19(7):2006-2019. [Abstract]

Zenidolol (ICI; 10 μM; 2 h) abolishes the Epinephrine-induced phosphorylation of CREB1 in MC38 and HT-29 cells.
J Exp Med

IL-6 translation is a therapeutic target of human cytokine release syndrome. [Abstract]

2023 Nov 6;220(11):e20230577. PMID: 37584653
J Pharm Anal

Baicalin reduces chronic stress-induced breast cancer metastasis via directly targeting β2-adrenergic receptor. [Abstract]

2024 Jul;14(7):100934. PMID: 39139999
Diabetes

Hepatokine ERAP1 Disturbs Skeletal Muscle Insulin Sensitivity Via Inhibiting USP33-Mediated ADRB2 Deubiquitination. [Abstract]

2022 May 1;71(5):921-933. PMID: 35192681
Chin Med J (Engl)

Skin-localized sympathetic nerve-keratinocyte crosstalk fuels psoriatic inflammation via neutrophil recruitment. [Abstract]

2026 Apr 23. PMID: 42036893
Int J Nanomedicine

Bupivacaine Nanoparticles Inhibit Triple-Negative Breast Tumor Growth by Suppressing the Noradrenergic Nerves in Tumor Microenvironment. [Abstract]

2025 May 12:20:6023-6041. PMID: 40385493
Cell Rep

β2AR as a target in methamphetamine addiction: Divergent mechanisms from TAAR1. [Abstract]

2025 Sep 23;44(10):116337. PMID: 40991929
Br J Pharmacol

Pharmacological targeting of β2 -adrenoceptors is neuroprotective in the LPS inflammatory rat model of Parkinson's disease. [Abstract]

2020 Jan;177(2):282-297. PMID: 31506926
Anal Chem

An Allosteric Assay for Identifying Ligands Binding to β2 Adrenergic Receptor by Surface-Enhanced Raman Scattering (SERS)-Active Nanoparticles. [Abstract]

2026 Feb 17;98(6):4895-4904. PMID: 41637639
Commun Biol

Suppression of trabecular meshwork phagocytosis by norepinephrine is associated with nocturnal increase in intraocular pressure in mice. [Abstract]

2022 Apr 8;5(1):339. PMID: 35396348
Commun Biol

Reserpine improves Enterobacteriaceae resistance in chicken intestine via neuro-immunometabolic signaling and MEK1/2 activation. [Abstract]

2021 Dec 3;4(1):1359. PMID: 34862463
J Endocrinol

β2AR against myocarditis-lipid deposition depends on estrogenic environment in stress. [Abstract]

2023 Feb 16;256(3):e220335. PMID: 36633355
Eur J Pharmacol

Dopamine regulates astrocytic IL-6 expression and process formation via dopamine receptors and adrenoceptors. [Abstract]

2022 Aug 5:928:175110. PMID: 35738452
Invest Ophthalmol Vis Sci

Activation of Sympathetic Nervous System Drives Dry Eye Onset Via Norepinephrine-β2-Adrenergic Receptor Signaling in Mice. [Abstract]

2025 Jun 2;66(6):13. PMID: 40465266
Int Dent J

Blocking β2-AR and Inhibiting COX-2: A Promising Approach to Suppress OSCC Development. [Abstract]

2025 Apr;75(2):807-816. PMID: 39043526
J Nutr Biochem

Genistein rescues hypoxia-induced pulmonary arterial hypertension through estrogen receptor and β-adrenoceptor signaling. [Abstract]

2018 Aug:58:110-118. PMID: 29886191

Zenidolol purchased from MedChemExpress. Usage Cited in: J Nutr Biochem. 2018 Aug:58:110-118. [Abstract]

PASMCs are pretreated with or not Norepinephrine (50 μM) or ICI 118,551 (5 nM), and α-SMA (D) are analyzed.
Oncol Rep

Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib. [Abstract]

2016 Sep;36(3):1576-84. PMID: 27432558

Zenidolol purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2016 Sep;36(3):1576-84. [Abstract]

Western blotting of Bcl-2 expression in 8505C lysates after in vitro pharmacologic interventions using propranolol and ICI118551 for 24 h. Western blotting of AKT, p-AKT, mTOR, p-mTOR in 8505C lysates after in vitro pharmacologic interventions using propranolol and ICI118551for 24 h.
Mol Oncol

NNK from tobacco smoking enhances pancreatic cancer cell stemness and chemoresistance by creating a β2AR-Akt feedback loop that activates autophagy. [Abstract]

2022 Aug;16(15):2881-2895. PMID: 35593085
BMC Cancer

β2AR-HIF-1α-CXCL12 signaling of osteoblasts activated by isoproterenol promotes migration and invasion of prostate cancer cells. [Abstract]

2019 Nov 26;19(1):1142. PMID: 31771535
Neuroscience

Natural Killer Cells may Exert Antidepressant-like Effects in Mice by Controlling the Release of Inflammatory Factors. [Abstract]

2019 Mar 1:401:59-72. PMID: 30641114
Pflugers Arch

Increased β-adrenergic stimulation augments vascular smooth muscle cell calcification via PKA/CREB signalling. [Abstract]

2021 Dec;473(12):1899-1910. PMID: 34564739
Biochem Biophys Res Commun

Olodaterol promotes thermogenesis in brown adipocytes via regulation of the β2-AR/cAMP/PKA signaling pathway. [Abstract]

2024 Apr 9:703:149689. PMID: 38382361
J Oral Maxillofac Surg

Overexpression of β-Adrenergic Receptors and the Suppressive Effect of β2-Adrenergic Receptor Blockade in Oral Squamous Cell Carcinoma. [Abstract]

2020 Oct;78(10):1871.e1-1871.e23. PMID: 32640209
BMC Ophthalmol

β-blocker eye drops affect ocular surface through β2 adrenoceptor of corneal limbal stem cells. [Abstract]

2021 Dec 5;21(1):419. PMID: 34863129
bioRxiv

Netrin-1 promotes pancreatic tumorigenesis and innervation through NEO1. [Abstract]

2025 Jul 26:2025.07.22.666009. PMID: 40777309
Environ Toxicol

Phenylacetyl glutamine (PAGln) enhances cardiomyocyte death after myocardial infarction through β1 adrenergic receptor. [Abstract]

2024 Mar;39(3):1682-1699. PMID: 38041472
bioRxiv

2024 Feb 19.
Biomed Pharmacother

Interference of sympathetic overactivation restores limbal stem/progenitor cells function and accelerates corneal epithelial wound healing in diabetic mice. [Abstract]

2023 May:161:114523. PMID: 36931034
Research Square Preprint

2022 Mar.
Research Square Preprint

2021 Nov.
Research Square Preprint

2021 Sep.
Research Square Preprint

2021 Feb.
Research Square Preprint

2020 Oct.
bioRxiv

2020 Jan.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (360.49 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.6049 mL

18.0245 mL

36.0490 mL

5 mM

0.7210 mL

3.6049 mL

7.2098 mL

10 mM

0.3605 mL

1.8025 mL

3.6049 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (18.02 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (18.02 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (290 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Cuesta AM, et al. The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease. Sci Rep. 2019;9(1):10062. Published 2019 Jul 11. [Content Brief]

[2]. Bilski, Andrew J., et al. The pharmacology of a β2-selective adrenoceptor antagonist (ICI 118,551). Journal of cardiovascular pharmacology 5.3 (1983): 430-437.

[3]. Nathanson JA, et al. ICI 118,551: an effective ocular hypotensive agent with selectivity for the ciliary process beta 2-adrenoceptor and with minimal cardiac side effects. Br J Pharmacol. 1984;83(3):821-829. [Content Brief]

[4]. Wenzel, Daniela, et al. β2-Adrenoceptor antagonist ICI 118,551 decreases pulmonary vascular tone in mice via a Gi/o protein/nitric oxide-coupled pathway. Hypertension 54.1 (2009): 157-163.

[5]. Hoffmann C, et al. Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.6049 mL	18.0245 mL	36.0490 mL	90.1226 mL
	5 mM	0.7210 mL	3.6049 mL	7.2098 mL	18.0245 mL
	10 mM	0.3605 mL	1.8025 mL	3.6049 mL	9.0123 mL
	15 mM	0.2403 mL	1.2016 mL	2.4033 mL	6.0082 mL
	20 mM	0.1802 mL	0.9012 mL	1.8025 mL	4.5061 mL
	25 mM	0.1442 mL	0.7210 mL	1.4420 mL	3.6049 mL
	30 mM	0.1202 mL	0.6008 mL	1.2016 mL	3.0041 mL
	40 mM	0.0901 mL	0.4506 mL	0.9012 mL	2.2531 mL
	50 mM	0.0721 mL	0.3605 mL	0.7210 mL	1.8025 mL
	60 mM	0.0601 mL	0.3004 mL	0.6008 mL	1.5020 mL
	80 mM	0.0451 mL	0.2253 mL	0.4506 mL	1.1265 mL
	100 mM	0.0360 mL	0.1802 mL	0.3605 mL	0.9012 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Zenidolol

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Neurotransmitter Receptor Compound Library

Glutamine Metabolism Compound Library

Anti-Alzheimer's Disease Compound Library

Anti-Breast Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Antidepressant Compound Library

Cancer Stem Cells Compound Library

Antihypertensive Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Apoptosis Compound Library

Epigenetics Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Neuronal Signaling Compound Library

Publications Citing Use of MedChemExpress (MCE) Zenidolol

All Adrenergic Receptor Isoforms

All Caspase Isoforms

All Bcl-2 Family Isoforms

All HIF/HIF Prolyl-Hydroxylase Isoforms

Biological Activity

Chemical Information

Publications (47)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Zenidolol Related Classifications

HY-100543 Related Classifications